文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

曲磷胺对比多柔比星治疗老年转移性软组织肉瘤的随机II期试验

Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma.
PubMed 文献 · Eur J Cancer · 2019-11-28

B组6个月无进展率(主要终点)为27.6%,A组为35.9%;B组严重不良事件发生率显著低于A组(30.3% vs 59%,p=0.005)。口服曲磷胺达到预设主要终点,且毒性谱较多柔比星更有利。

要点

  • 曲磷胺组6个月无进展率27.6%,多柔比星组35.9%,主要终点被超过。
  • 曲磷胺组严重不良事件发生率30.3%,显著低于多柔比星组的59%。
  • 曲磷胺更常见呼吸困难与低级别乏力,多柔比星更常见白细胞减少、中性粒细胞减少和黏膜炎。

核心结论

  • 在老年转移性软组织肉瘤患者中,口服曲磷胺达到了预设的6个月无进展率主要终点。
  • 与多柔比星相比,曲磷胺的毒性谱更有利。

研究设计与样本

  • 随机对照II期试验,按1:2将120例既往未治疗、年龄>60岁、ECOG评分0-2的软组织肉瘤患者分配至多柔比星组(A组,6周期)或口服曲磷胺组(B组)。

主要发现

  • 6个月无进展率:B组27.6%(95%CI 18.0-39.1),A组35.9%(95%CI 21.2-52.8)。
  • 中位无进展生存期:B组4.3个月(95%CI 2.2-6.3),A组2.8个月(95%CI 1.7-3.6)。
  • 中位总生存期:B组9.8个月(95%CI 6.7-11.6),A组12.3个月(95%CI 9.6-16.2)。
  • 严重不良事件发生率:A组59%,B组30.3%(p=0.005)。
  • 非疾病进展原因的停药率:A组15.4%,B组7.9%。

关键数值与推荐

  • 主要终点为实验组6个月无进展率,预设阈值未在摘要中报告。
  • 曲磷胺组更常见呼吸困难和低级别乏力,多柔比星组更常见白细胞减少、中性粒细胞减少和黏膜炎。

临床怎么用

  • 对于老年转移性软组织肉瘤患者,口服曲磷胺可作为毒性更低的替代选择,尤其适合关注严重不良事件风险的患者。
  • 治疗选择需权衡曲磷胺较低的严重不良事件发生率与多柔比星较长的总生存期趋势。

局限性

  • 为II期试验,样本量120例,主要终点为6个月无进展率而非总生存期。
  • 摘要未报告预设的6个月无进展率阈值及统计学比较结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Doxorubicin represents the standard first-line treatment for metastatic soft-tissue sarcoma. We assessed the efficacy and safety of trofosfamide in elderly patients. In this controlled phase II trial, we randomly (1:2) assigned 120 previously untreated patients with soft-tissue sarcoma, older than 60 years, with an Eastern Cooperative Oncology Group score of 0-2, to receive either doxorubicin for 6 cycles (arm A) or oral trofosfamide (arm B). The primary end-point was a 6-month progression-free rate (PFR) in the experimental arm (clinical trial information: NCT00204568). Between August 2004 and October 2012, forty and 80 patients were randomly assigned to arm A and arm B, respectively, in 16 centres. The median age was 70 years (range, 60-89). The primary study end-point (6-month PFR) was exceeded, with 27.6% in arm B (95% confidence interval [CI], 18.0-39.1) and 35.9% in arm A: (95% CI, 21.2-52.8). Survival data in terms of progression-free survival were 4.3 months (95% CI, 2.2-6.3) and 2.8 months (95% CI, 1.7-3.6) and in terms of overall survival were 9.8 months (95% CI, 6.7-11.6) and 12.3 months (95% CI, 9.6-16.2), respectively. The number of serious adverse event (SAE) was 59% in arm A and 30.3% in arm B (p = 0.005). Trofosfamide caused more often dyspnoea and low-grade fatigue, whereas with doxorubicin, more often leukocytopenia, neutropenia and mucositis were seen. Discontinuation rates for reasons other than disease progression were 15.4% (arm A) vs. 7.9% (arm B). In an elderly population of patients, oral trofosfamide achieved the estimated primary end-point 6-month PFR and was associated with a favourable toxicity profile compared with doxorubicin.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hartmann JT, Kopp HG, Gruenwald V, et al. Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. Eur J Cancer. 2019. PMID: 31785463. doi:10.1016/j.ejca.2019.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。